Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) just unveiled an announcement.
Hangzhou Tigermed Consulting reported modest revenue growth for 2025, with sales rising 3.5% year-on-year to RMB 6.83 billion, while gross profit declined 16.4% and gross margin fell to 27.4%, highlighting pressure on operating efficiency. Despite this, net profit attributable to owners more than doubled to RMB 887.9 million and basic earnings per share rose 121.3% to RMB 1.04, helped by non-recurring items as evidenced by a 58.5% drop in adjusted net profit after extraordinary gains or losses.
The company’s balance sheet remained solid, with total assets roughly flat at RMB 28.36 billion, equity attributable to owners edging up 1.4%, total liabilities down 10.9% and the gearing ratio reduced to 4.6%, although cash and cash equivalents declined 15.9%. The board proposed a final dividend of RMB 1.26 per 10 shares, signaling confidence in cash generation and capital strength, even as underlying profitability pressures and lower core margins may concern investors tracking the sustainability of earnings quality.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$61.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a China-based contract research organization serving the pharmaceutical and biotech industries. The company provides clinical trial, regulatory and related consulting services, supporting drug development and commercialization for domestic and international clients, and is listed in Hong Kong as a Class H share issuer.
YTD Price Performance: -2.63%
Average Trading Volume: 2,034,252
Technical Sentiment Signal: Sell
Current Market Cap: HK$46.16B
For detailed information about 3347 stock, go to TipRanks’ Stock Analysis page.